세계의 알코올성 간 질환 치료 시장 보고서(-2031년) : 동향, 예측, 경쟁 분석
Alcoholic Liver Disease Treatment Market Report: Trends, Forecast and Competitive Analysis to 2031
상품코드 : 1823956
리서치사 : Lucintel
발행일 : 2025년 09월
페이지 정보 : 영문 150 Pages
 라이선스 & 가격 (부가세 별도)
US $ 3,850 ₩ 5,558,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. PDF 파일은 DRM(디지털 저작권 관리 시스템)이 장착되어 있습니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 4,650 ₩ 6,713,000
PDF (2 Users License) help
PDF 보고서를 동일 사업장에서 2명까지 이용할 수 있는 라이선스입니다. PDF 파일은 DRM(디지털 저작권 관리 시스템)이 장착되어 있습니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 5,350 ₩ 7,724,000
PDF (5 Users License) help
PDF 보고서를 동일 사업장에서 5명까지 이용할 수 있는 라이선스입니다. PDF 파일은 DRM(디지털 저작권 관리 시스템)이 장착되어 있습니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 7,050 ₩ 10,178,000
PDF (Corporate License) help
PDF 보고서를 기업 내 모든 분이 이용할 수 있는 라이선스입니다. 이용 인원에 제한은 없으나, 국내에 있는 사업장만 해당되며, 해외 지점 등은 포함되지 않습니다. PDF 파일은 DRM(디지털 저작권 관리 시스템)이 장착되어 있습니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

세계의 알코올성 간 질환 치료 시장 전망은 병원 약국, 소매 약국, 약국, 온라인 약국의 각 시장에서 기회에 유망시되고 있습니다. 세계 알코올성 간 질환 치료 시장은 2025-2031년 연평균 복합 성장률(CAGR) 7.4%를 보일 것으로 예측됩니다. 이 시장의 주요 촉진요인은 알코올 섭취량 증가, 간 건강에 대한 의식 증가, 치료법의 진보입니다.

알코올성 간 질환 치료 시장의 새로운 동향

알코올성 간 질환 치료는 다면적 병태에 대한 통찰력의 깊어짐과 보다 새로운, 보다 효능이 높은 치료법에 대한 수요에 힘입어 역동적인 변화의 과정에 있습니다. 이러한 새로운 동향은 기존의 지지 요법에 그치지 않고, 표적 요법이나 맞춤형 의료에의 문을 열고 있습니다.

이러한 새로운 동향은 창약의 기술 혁신을 촉진하고, 개별화 전략을 장려하고, 마이크로바이옴 조절이나 재생 의료 등의 새로운 치료 기회를 조사하고, 디지털 기술을 통해 지지 요법을 최적화함으로써 ALD 치료 시장을 재정의하고 있습니다. 이 종합적인 변화는 세계적으로 증가하는 알코올성 간 질환의 부담을 관리하고 환자의 예후를 개선하는 데 필수적입니다.

알코올성 간 질환 치료 시장의 최근 동향

알코올성 간 질환 치료 시장은 알코올성 간 질환에 대한 지식의 향상, 알코올 관련 피해의 세계적인 발생률 증가, 보다 우수한 치료법의 급성기의 필요성 등에 힘입어 최근에 큰 진보를 이루고 있습니다. 이러한 진보는 기존의 관리 접근 방식에 혁명을 가져오고 환자에게 새로운 희망을 가져다 줍니다.

이러한 뚜렷한 진보는 보다 적극적이고 전반적인 환자에 초점을 맞춘 접근 방식을 통해 ALD 치료 시장에 누적 영향을 미칩니다. 이들은 새로운 치료법의 개발을 추진하고, 진단 기능을 발전시키고, 중요한 중독 치료를 도입함으로써, 알코올성 간 질환으로 고통받는 사람들의 예후와 삶의 질을 향상시키기 위해 노력하고 있습니다.

목차

제1장 주요 요약

제2장 시장 개요

제3장 시장 동향과 예측 분석

제4장 세계의 알코올성 간 질환 치료 시장 : 유형별

제5장 세계의 알코올성 간 질환 치료 시장 : 용도별

제6장 지역 분석

제7장 북미의 알코올성 간 질환 치료 시장

제8장 유럽의 알코올성 간 질환 치료 시장

제9장 아시아태평양의 알코올성 간 질환 치료 시장

제10장 기타 지역(ROW)의 알코올성 간 질환 치료 시장

제11장 경쟁 분석

제12장 기회와 전략 분석

제13장 밸류체인의 주요 기업 프로파일

제14장 부록

JHS
영문 목차

영문목차

The future of the global alcoholic liver disease treatment market looks promising with opportunities in the hospital pharmacy, retail pharmacy, drug store, and online pharmacy markets. The global alcoholic liver disease treatment market is expected to grow with a CAGR of 7.4% from 2025 to 2031. The major drivers for this market are the increasing prevalence of alcohol consumption, the rising awareness about liver health, and the growing advancements in medical treatments.

Emerging Trends in the Alcoholic Liver Disease Treatment Market

The alcoholic liver disease treatment is in a process of dynamic transformation, fueled by increased insight into the multifaceted pathogenesis of the disease and the imperative for newer, more efficacious therapeutic alternatives. These emerging trends are proceeding beyond conventional supportive therapy, opening the doors to targeted therapies and individualized medicine.

These new trends together are redefining the ALD treatment market by driving innovation in drug discovery, encouraging individualized strategies, investigating new therapeutic opportunities such as microbiome modulation and regenerative medicine, and optimizing supportive care through digital technologies. This comprehensive transformation is essential for managing the increasing global alcohol liver disease burden and enhancing prognosis in patients.

Recent Developments in the Alcoholic Liver Disease Treatment Market

The alcoholic liver disease treatment market has experienced substantial recent advances, driven by improved knowledge of the disease, growing global incidence of alcohol-related harm, and the need for better therapies acutely. These advances are revolutionizing old-fashioned management approaches, bringing new hope to patients.

These salient advancements are cumulatively affecting the ALD treatment market through a more targeted, holistic, and patient-focused approach. They are propelling the development of new therapies, advancing diagnostic functions, and incorporating vital addiction care, all working towards enhancing the prognosis and quality of life of those suffering from alcoholic liver disease.

Strategic Growth Opportunities in the Alcoholic Liver Disease Treatment Market

There are significant strategic growth opportunities for the alcoholic liver disease treatment market across all applications, fueled by the growing global disease burden and the pressing need for successful interventions. Capitalizing on these opportunities involves a multi-faceted strategy, addressing particular patient requirements and disease phases.

These strategic growth opportunities are collectively shaping the ALD treatment market by spurring innovation along the disease continuum, from early intervention to advanced care and relapse prevention. This integrated approach is needed to meet the complex challenges of alcoholic liver disease and enhance patient prognosis worldwide.

Alcoholic Liver Disease Treatment Market Driver and Challenges

The alcoholic liver disease treatment market is shaped by a complex interplay of major drivers pushing its growth and major challenges that require continuous research, strategic investment, and policy reforms. These include multiple technological, economic, and regulatory factors.

The factors responsible for driving the alcoholic liver disease treatment market include:

1. Increased Global Alcohol Consumption and ALD Incidence: One main driver is the steady per capita alcohol consumption worldwide, especially in the growing economies, resulting in an increase in ALD incidence. This expanding patient base directly drives demand for diagnostic equipment and treatment measures across the disease continuum, from alcoholic fatty liver to cirrhosis and alcoholic hepatitis. The rising public health problem calls for innovative and affordable treatments.

2. Progress in Disease Pathogenesis Knowledge: Recent advances in deciphering the intricate molecular and cellular processes of ALD, such as inflammation, oxidative stress, and dysbiosis of the gut, are major driving forces. Greater knowledge facilitates the identification of new therapeutic targets and the generation of more specific and potent drug candidates beyond symptomatic relief to target underlying disease mechanisms.

3. Stepped-up Research and Development Spending: Pharma and biotech firms are greatly upping their R&D spending on ALD therapies, aware of the strong unmet medical demand and marketplace potential. This investment is speeding up drug discovery, funding clinical trials for new drugs, and investigating next-generation treatments like regenerative medicine. The emphasis is on the creation of more effective and less side-effect-prone drugs.

4. Enhanced Diagnostic Performance: Advances and increased use of non-invasive diagnostic equipment, like transient elastography (Fibro Scan) and sophisticated biomarkers, are pushing the detection of ALD to earlier and more precise levels. Early detection makes it possible to undertake intervention, which can prevent or halt the development of the disease, thus boosting the requirement for effective therapy at more advanced stages. Proactive detection enhances patient outcomes.

5. Increasing Public Awareness and Public Health Measures: Increasing campaigns among the general public regarding the risks of excessive drinking and the need for early diagnosis of liver disease are major drivers. The measures, usually funded by governments and non-governmental agencies, translate into early diagnosis, higher patient compliance with treatment, and a community drive towards improved ALD prevention and management.

Challenges in the alcoholic liver disease treatment market are:

1. Limited FDA-Approved Specific Therapies for Alcoholic Hepatitis: The greatest challenge is the pressing unmet need for specific, FDA-approved pharmacotherapy for severe alcoholic hepatitis (AH). Treatment is largely dependent on corticosteroids, which are of modest efficacy and have serious side effects, or liver transplantation, which is subject to severe restriction by criteria and availability of donors. This deficiency clearly emphasizes the pressing need for effective drug discovery.

2. Adherence of the Patient to Abstinence and Treatment Regimens: A basic problem in the treatment of ALD is to maintain prolonged alcohol abstinence, a prerequisite to reverse or stabilize the disease. Adherence to alcohol cessation programs, medication, and lifestyle modifications by the patient may be challenging given alcohol's addictive properties and psychosocial influences, tending to result in relapse and progression of the disease despite medical efforts.

3. Disease Complexity and Patient Heterogeneity in Disease Response: ALD is a heterogeneous condition, with differing progression and patient responses to therapy as a result of genetic, environmental, and individual factors. This makes it hard to create generalizable "one-size-fits-all" treatments and requires individualized approaches, which are hard to roll out on a large scale and tend to be costly.

Summarily, the treatment market of alcoholic liver disease is under dynamic growth pressure caused by mounting global alcohol-induced liver damage burden, greater insight into disease mechanisms, more R&D spending, and better diagnostic capabilities. The increasing public awareness also contributes to that. Yet, the market is confronted with some major challenges, most importantly the grave shortage of certain approved treatments for severe alcoholic hepatitis, the critical challenge of patient compliance with abstinence, and the inherent complexity and heterogeneity of the disease itself.

List of Alcoholic Liver Disease Treatment Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies alcoholic liver disease treatment companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the alcoholic liver disease treatment companies profiled in this report include-

Alcoholic Liver Disease Treatment Market by Segment

The study includes a forecast for the global alcoholic liver disease treatment market by type, application, and region.

Alcoholic Liver Disease Treatment Market by Type [Value from 2019 to 2031]:

Alcoholic Liver Disease Treatment Market by Application [Value from 2019 to 2031]:

Alcoholic Liver Disease Treatment Market by Region [Value from 2019 to 2031]:

Country Wise Outlook for the Alcoholic Liver Disease Treatment Market

The market for alcoholic liver disease treatment is witnessing a dramatic shift, fueled by the increasing global burden of alcohol-induced liver injury and advances in medical science. Abstinence and supportive therapy have been the hallmark of treatment, but the latest advances in the recognition of the pathogenesis of disease have opened the doors to new therapeutic maneuvers. This revolution is witnessing greater spending on drug discovery, regenerative therapy, and customized treatment strategies, with the goal of enhancing patient outcomes at all levels of ALD, ranging from fatty liver to late-stage cirrhosis.

Features of the Global Alcoholic Liver Disease Treatment Market

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

Table of Contents

1. Executive Summary

2. Market Overview

3. Market Trends & Forecast Analysis

4. Global Alcoholic Liver Disease Treatment Market by Type

5. Global Alcoholic Liver Disease Treatment Market by Application

6. Regional Analysis

7. North American Alcoholic Liver Disease Treatment Market

8. European Alcoholic Liver Disease Treatment Market

9. APAC Alcoholic Liver Disease Treatment Market

10. ROW Alcoholic Liver Disease Treatment Market

11. Competitor Analysis

12. Opportunities & Strategic Analysis

13. Company Profiles of the Leading Players Across the Value Chain

14. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기